These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8533555)

  • 21. Disposition of infusions of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU.
    Parker CJ; Jones JE; Hunter JM
    Br J Anaesth; 1988 Nov; 61(5):531-40. PubMed ID: 3207525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic modelling of a parent drug and its metabolite. Atracurium and laudanosine.
    Nigrovic V; Banoub M
    Clin Pharmacokinet; 1992 May; 22(5):396-408. PubMed ID: 1505145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concentrations of atracurium and laudanosine in cerebrospinal fluid and plasma in three intensive care patients.
    Gwinnutt CL; Eddleston JM; Edwards D; Pollard BJ
    Br J Anaesth; 1990 Dec; 65(6):829-32. PubMed ID: 2265055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The future of the benzylisoquinolinium relaxants.
    Savarese JJ; Wastila WB
    Acta Anaesthesiol Scand Suppl; 1995; 106():91-3. PubMed ID: 8533554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamics and atracurium and laudanosine concentrations during a fixed continuous infusion of atracurium in mechanically ventilated patients with acute respiratory distress syndrome.
    Lefrant JY; Farenc C; De la Coussaye JE; Muller L; Ripart J; Cuvillon P; Saissi G; Eledjam JJ
    Anaesth Intensive Care; 2002 Aug; 30(4):422-7. PubMed ID: 12180578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atracurium infusions in patients with fulminant hepatic failure awaiting liver transplantation.
    Bion JF; Bowden MI; Chow B; Honisberger L; Weatherley BC
    Intensive Care Med; 1993; 19 Suppl 2():S94-8. PubMed ID: 8106686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function.
    Head-Rapson AG; Devlin JC; Parker CJ; Hunter JM
    Br J Anaesth; 1995 Jul; 75(1):31-6. PubMed ID: 7669465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium.
    Varin F; Ducharme J; Théorêt Y; Besner JG; Bevan DR; Donati F
    Clin Pharmacol Ther; 1990 Jul; 48(1):18-25. PubMed ID: 2369806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of laudanosine, an atracurium metabolite, following a fatal drug-related shooting.
    Logan BK; Case GA
    J Anal Toxicol; 1993; 17(2):117-9. PubMed ID: 8492564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic-pharmacodynamic modeling of atracurium in intensive care patients.
    Farenc C; Lefrant JY; Audran M; Bressolle F
    J Clin Pharmacol; 2001 Jan; 41(1):44-50. PubMed ID: 11144993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intubating conditions following 1R CIS, 1'R CIS atracurium (51W89). A comparison with atracurium.
    Littlejohn IH; Abhay K; el Sayed A; Broomhead CJ; Duvaldestin P; Flynn PJ
    Anaesthesia; 1995 Jun; 50(6):499-502. PubMed ID: 7618661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery.
    Asokumar B; Cheng D; Chung F; Peniston C; Sandler A; Varin F
    Can J Anaesth; 1998 Jun; 45(6):515-20. PubMed ID: 9669003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New muscle relaxants].
    Diefenbach C; Buzello W
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 Feb; 31(1):2-8. PubMed ID: 8868525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of atracurium and its metabolites in patients with normal renal function, and in patients in renal failure.
    Ward S; Boheimer N; Weatherley BC; Simmonds RJ; Dopson TA
    Br J Anaesth; 1987 Jun; 59(6):697-706. PubMed ID: 3606914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of urinary and biliary conjugated metabolites of the neuromuscular blocker 51W89 by liquid chromatography/mass spectrometry.
    Dear GJ; Harrelson JC; Jones AE; Johnson TE; Pleasance S
    Rapid Commun Mass Spectrom; 1995; 9(14):1457-64. PubMed ID: 8534894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concentrations of atracurium and laudanosine in cerebrospinal fluid and plasma during intracranial surgery.
    Eddleston JM; Harper NJ; Pollard BJ; Edwards D; Gwinnutt CL
    Br J Anaesth; 1989 Nov; 63(5):525-30. PubMed ID: 2605068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function.
    Vandenbrom RH; Wierda JM; Agoston S
    Clin Pharmacokinet; 1990 Sep; 19(3):230-40. PubMed ID: 2394062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Newer neuromuscular blocking agents: how do they compare with established agents?
    Sparr HJ; Beaufort TM; Fuchs-Buder T
    Drugs; 2001; 61(7):919-42. PubMed ID: 11434449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of the organ-independent elimination of cisatracurium.
    Kisor DF; Schmith VD; Wargin WA; Lien CA; Ornstein E; Cook DR
    Anesth Analg; 1996 Nov; 83(5):1065-71. PubMed ID: 8895287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia.
    Lien CA; Schmith VD; Embree PB; Belmont MR; Wargin WA; Savarese JJ
    Anesthesiology; 1994 Jun; 80(6):1296-302. PubMed ID: 8010476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.